Gilead Sciences (GILD) director sells 5,000 shares near $146
Gilead Sciences (GILD) director Jeffrey Bluestone exercised non-qualified stock options for 5,000 shares and subsequently sold all 5,000 shares for approximately $725,000. These transactions occurred on August 20, 2026, at prices ranging from $143.31 to $146.36 per share, following a Rule 10b5-1 trading plan. Bluestone's total holdings after these transactions include 11,395 non-qualified stock options and 10,066 common stock shares.
TG Therapeutics (TGTX) Stock Still Looks Cheap Even After Strong Returns
TG Therapeutics (TGTX) has shown impressive returns of 388.0% over three years, yet its stock appears undervalued based on various valuation checks. The company's P/E ratio of 16.2x is below both the biotech industry average and its peer group, suggesting it's priced lower than its implied fair value. While there's a strong bull case around its drug BRIUMVI, risks include reliance on this single revenue source and potential competitive threats.
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?
This article compares two Invesco biotech ETFs, IBBQ and PBE, highlighting their different investment strategies. IBBQ offers broad diversification across 251 companies with a lower expense ratio, while PBE employs a concentrated, quant-driven approach with 31 holdings and a higher dividend yield. The analysis helps investors determine which ETF aligns better with their investment goals, considering factors like expense ratios, diversification, and dividend yields.
Portfolio Design Labs LLC Takes $1.29 Million Position in Gilead Sciences, Inc. $GILD
Portfolio Design Labs LLC has acquired a new position of 10,178 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $1.29 million, during the second quarter. This move is part of a broader trend where other institutional investors have also increased their stakes in the biopharmaceutical company. Analysts currently rate GILD as a "Moderate Buy" with an average price target of $158.04, despite recent insider selling and mixed long-term earnings forecasts.
PCM Encore LLC Buys Shares of 7,399 Gilead Sciences, Inc. $GILD
PCM Encore LLC acquired 7,399 shares of Gilead Sciences, Inc., valued at approximately $935,000, as part of broader institutional investment in the biopharmaceutical company. Analysts maintain a "Moderate Buy" consensus with an average price target of $158.04, following Gilead's strong quarterly revenue of $7.80 billion and a declared dividend of $0.82 per share. Despite some insider selling, the overall sentiment remains positive, driven by collaborations and pipeline developments.
14,265 Shares in Gilead Sciences, Inc. $GILD Purchased by OVERSEA CHINESE BANKING Corp Ltd
OVERSEA CHINESE BANKING Corp Ltd recently acquired 14,265 shares of Gilead Sciences (NASDAQ:GILD) valued at approximately $1.8 million during the second quarter. This purchase is part of broader institutional investment trends, with several other major firms also initiating or increasing their positions in Gilead Sciences. Analysts have a "Moderate Buy" consensus rating for the stock, with an average price target of $158.04, despite recent insider sales and a negative P/E ratio.
Vise Technologies Inc. Takes $15.17 Million Position in Gilead Sciences, Inc. $GILD
Vise Technologies Inc. has acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD), purchasing 120,100 shares valued at approximately $15.17 million during the second quarter. This move comes as other institutional investors have also modified their holdings in the biopharmaceutical company, while insiders have recently sold shares totaling over $5.8 million. Analyst ratings for Gilead Sciences currently lean towards a "Moderate Buy" with an average price target of $158.04, amidst recent dividend announcements and varied news impacting the stock.
Allworth Financial LP Invests $5.96 Million in Gilead Sciences, Inc. $GILD
Allworth Financial LP has acquired a new stake of 47,192 shares, valued at approximately $5.96 million, in Gilead Sciences, Inc. during the second quarter. This investment is part of broader institutional activity, with other major firms like BlackRock Inc. and Vanguard Group Inc. also holding substantial positions or adjusting their stakes in the biopharmaceutical company. Gilead Sciences recently reported earnings that beat analyst estimates and declared a quarterly dividend, while facing some mixed sentiment from analysts regarding its future earnings trajectory.
B. Metzler seel. Sohn & Co. AG Purchases New Position in Gilead Sciences, Inc. $GILD
B. Metzler seel. Sohn & Co. AG has acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD), purchasing 114,360 shares valued at approximately $14.4 million in the second quarter. Other institutional investors also made significant purchases, bringing total institutional ownership to 83.67%. The article highlights Gilead's strong quarterly revenue, dividend declaration, positive analyst sentiment, and recent insider trading activity.
Altman Advisors Inc. Takes Position in Gilead Sciences, Inc. $GILD
Altman Advisors Inc. initiated a new position in Gilead Sciences, Inc. during the second quarter, purchasing 21,931 shares valued at approximately $2.77 million. This move is part of broader institutional interest, as Gilead reported strong quarterly revenue growth and a dividend declaration. Despite some insider selling, analysts maintain a "Moderate Buy" rating for the biopharmaceutical company.
Gilead (NASDAQ: GILD) director to sell 5,000 shares in 2026
A director at Gilead Sciences, Inc. (NASDAQ: GILD), Jeffrey Bluestone, has filed a notice under Rule 144 to sell 5,000 shares of common stock. The proposed sale, valued at approximately $738,000, is expected around August 20, 2026, following the exercise of stock options for cash. The transaction will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services.
Macrogenics senior VP sells $129,085 in shares
Jeffrey Stuart Peters, Senior VP at MacroGenics Inc., sold 31,105 shares of company common stock for $129,085 on August 19, 2026, as part of a Rule 10b5-1 trading plan. This insider sale follows a 172% surge in MacroGenics shares over the past year. The company recently completed a $122.5 million sale of manufacturing operations to Bora Pharmaceuticals and expects a $24.5 million milestone payment from Sanofi for TZIELD's FDA approval, while also seeing Gilead Sciences exercise an option on a preclinical program.
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors
Gilead Sciences Inc. (GILD) shares dropped 2.82% to $143.44 on Thursday, underperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average, which also saw declines. This marked the end of a seven-day winning streak for the stock.
Eupraxia Pharmaceuticals Market Sentiment
This article provides an overview of market sentiment for Eupraxia Pharmaceuticals (EPRX), including analyst consensus, short interest, options flow, and insider activity. It highlights that 6 analysts have a "Buy" consensus with an average price target of $16, indicating a significant upside. The article also lists recent analyst actions with their ratings and price target changes.
Gilead Sciences Stock Surges 11%, With A 7-Day Winning Spree
Gilead Sciences (NASDAQ: GILD) stock has surged by 11% recently, marking a seven-day winning streak. This performance indicates significant positive movement for the company's shares.
Gilead Sciences Stock Climbs 11% On A 7-Day Winning Streak
Gilead Sciences (GILD) stock has seen an 11% increase over a seven-day winning streak, adding about $18 billion to its market value, now standing at $183 billion. This run is largely attributed to a sector-wide biotech rally, with the S&P 500 experiencing a slight decline during the same period. While Gilead exhibits strong fundamentals like a 38.5% operating margin and 7.1% free cash flow yield, its revenue growth trails the S&P 500 median, and a one-time acquisition charge resulted in negative trailing GAAP net earnings.
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in the life sciences sector, with a strong background in scaling organizations through growth and preparing for commercialization. His appointment comes as Nurix transitions from a research-focused company to a fully integrated biopharmaceutical organization, aiming to advance its clinical pipeline and prepare for the commercial launch of its targeted protein degradation medicines.
Westport Asset Management Inc. Acquires Shares of 10,000 Gilead Sciences, Inc. $GILD
Westport Asset Management Inc. recently acquired 10,000 shares of Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximately $1.26 million, contributing to the 83.67% institutional ownership of the company. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $158.04, reflecting a generally positive outlook. Gilead also reported strong quarterly revenue of $7.8 billion, a 10.6% year-over-year increase, and declared a quarterly dividend of $0.82.
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics (Nasdaq: NRIX) has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in life sciences and will join the company's Executive Management Team. His role will be crucial as Nurix transitions from a research and early clinical-stage company to a fully integrated biopharmaceutical organization, preparing for commercialization and scaling its operations.
NewEdge Wealth LLC Takes $95.26 Million Position in Gilead Sciences, Inc. $GILD
NewEdge Wealth LLC has acquired a significant stake of 754,019 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $95.26 million, making it their 19th largest holding. This comes as Gilead reported strong quarterly revenue of $7.8 billion, exceeding expectations, and declared a quarterly dividend of $0.82. Despite some executive share sales, analysts maintain a "Moderate Buy" consensus for the biopharmaceutical company.
Johnson Financial Group Inc. Invests $2.12 Million in Gilead Sciences, Inc. $GILD
Johnson Financial Group Inc. has acquired a new stake in Gilead Sciences, Inc., purchasing 16,791 shares valued at approximately $2.12 million. This investment comes amidst broad optimism from analysts, with a "Moderate Buy" consensus and an average target price of $158.04, following Gilead's reported quarterly revenue of $7.8 billion, exceeding expectations. The company also declared a quarterly dividend of $0.82 per share.
Knuff & Co LLC Buys Shares of 17,641 Gilead Sciences, Inc. $GILD
Knuff & Co LLC has acquired 17,641 shares of Gilead Sciences, Inc. for approximately $2.23 million, as reported in its recent SEC filing. Institutional investors now hold 83.67% of the company's stock, with other hedge funds also increasing their positions. Despite some insider selling under pre-arranged plans, analysts maintain a "Moderate Buy" rating for Gilead, citing strong quarterly revenue growth, a robust HIV portfolio, and a consistent dividend payout.
22,416 Shares in Gilead Sciences, Inc. $GILD Acquired by Csenge Advisory Group
Csenge Advisory Group has acquired a new stake of 22,416 shares in Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximately $2.83 million during the second quarter. Other institutional investors have also adjusted their holdings in the biopharmaceutical company. Analysts currently rate GILD as a "Moderate Buy" with a consensus price target of $158.04, despite some recent insider selling.
E Fund Management Co. Ltd. Acquires Shares of 53,836 Gilead Sciences, Inc. $GILD
E Fund Management Co. Ltd. has acquired 53,836 shares of Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximately $6.8 million during the second quarter. Institutional investors now collectively own 83.67% of the company's stock, with several other hedge funds also adjusting their holdings. Gilead reported strong quarterly revenue of $7.8 billion, exceeding estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $158.04, despite some insider share sales.
Great Lakes Advisors LLC Buys Shares of 62,450 Gilead Sciences, Inc. $GILD
Great Lakes Advisors LLC has acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD), purchasing 62,450 shares valued at approximately $7.89 million in the second quarter. This move is part of broader institutional investment, with various hedge funds modifying their holdings, and comes amidst Gilead reporting strong quarterly revenue of $7.8 billion, exceeding analyst expectations. Despite some insider selling, analysts maintain a "Moderate Buy" consensus rating for the biopharmaceutical company.
Foster & Motley Inc. Takes Position in Gilead Sciences, Inc. $GILD
Foster & Motley Inc. has acquired a new stake in Gilead Sciences, Inc. during the second quarter, purchasing 11,977 shares valued at approximately $1.51 million. The article also details increased institutional investor holdings, positive analyst sentiment, and an increase in EPS estimates for Gilead Sciences, alongside some insider stock sales and updated price targets from various research analysts.
Diversify Advisory Services LLC Invests $1.82 Million in Gilead Sciences, Inc. $GILD
Diversify Advisory Services LLC recently acquired a new stake of 13,919 shares, valued at $1.82 million, in Gilead Sciences, Inc. during the second quarter. Other institutional investors have also adjusted their holdings in GILD, with 83.67% of the stock owned by institutional investors and hedge funds. Analyst sentiment is mixed but largely positive, with several upgrades and price target increases, though some long-term estimates have been reduced and insiders have made sales under pre-arranged trading plans.
How Investors May Respond To CG Oncology (CGON) Revenue Growth Alongside a Widening Net Loss
CG Oncology (CGON) reported Q2 results showing increased revenue of US$1.16 million, but also a widening net loss of US$79.06 million, indicating it remains a research-driven company. The investment narrative hinges on the success of its drug cretostimogene, with clinical trial readouts being key catalysts despite escalating cash burn and financing risks. While the stock has seen a strong year-to-date run, the growing losses and varied fair value estimates suggest a high degree of uncertainty among investors.
People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management
Mineralys Therapeutics, Inc. has appointed Jessica Wagner Keliher, SPHR, as Vice President, Talent Management. Keliher brings over two decades of human resources leadership experience from the biotech and life sciences sectors, including previous roles at Cartesian Therapeutics, Novavax, and Kite Pharma. Her new role will focus on shaping the people and culture strategy as Mineralys Therapeutics prepares for the commercialization of its lead hypertension treatment, Lorundrostat.
Publicis wins Gilead Sciences' US media account
Publicis has been appointed to handle Gilead Sciences' U.S. media account. Gilead Sciences continues to demonstrate strong growth within its HIV product portfolio. The article highlights this significant win for Publicis in the pharmaceutical advertising sector.
Gilead Sciences Inc Stock (GILD) Moved Up by 3.66% on Aug 19: A Full Analysis
Gilead Sciences Inc (GILD) saw its stock price increase by 3.66% due to strong performance in its HIV portfolio, favorable regulatory developments, and positive analyst ratings. The company's raised full-year sales guidance and a federal court injunction protecting its market share contributed to investor confidence. Despite some risks like acquisition-related earnings drag and heavy revenue concentration in its HIV franchise, technical indicators show a buy signal.
ITOC, PTHL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) Securities Lawsuit - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has announced a securities class action lawsuit against iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd), naming director Pengfei Zhang as an individual defendant. The lawsuit alleges that Zhang oversaw public disclosures that omitted specific manipulation risks, leading to a 95% share value decline. Investors who purchased iTonic securities between September 5, 2024, and July 29, 2025, and suffered losses are encouraged to contact the firm by the lead plaintiff deadline of September 29, 2026.
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MaxCyte (NASDAQ: MXCT) has launched two new off-target nomination assays, CHANGE-seq-BE™ and ONE-seq-BE™, for adenine and cytosine base editors, offered through its SeQure™ gene editing risk assessment service. These assays aim to provide sensitive and unbiased biochemical assessment of off-target sites, with ONE-seq-BE uniquely offering visibility into population-specific genetic variants that could influence off-target activity. The company states that these tools will help therapeutic developers align with evolving regulatory expectations, including recent FDA guidance on genome safety, by building stronger data packages for clinical development.
Wealthfront Advisers LLC Takes Position in Gilead Sciences, Inc. $GILD
Wealthfront Advisers LLC has acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, purchasing shares valued at approximately $30.25 million. This comes amidst other institutional investors modifying their holdings and some insider selling activity, while analyst ratings present a "Moderate Buy" consensus for the biopharmaceutical company. Gilead Sciences recently reported earnings that beat analyst estimates and declared a quarterly dividend.
M. Kulyk & Associates LLC Buys New Position in Gilead Sciences, Inc. $GILD
M. Kulyk & Associates LLC has acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD), purchasing 74,859 shares valued at approximately $9.
Meeder Advisory Services Inc. Invests $4.42 Million in Gilead Sciences, Inc. $GILD
Meeder Advisory Services Inc. has invested $4.42 million in Gilead Sciences, Inc. by acquiring 34,965 shares during the second quarter, making it one of several institutional investors increasing their stake in the biopharmaceutical company. Gilead Sciences reported strong quarterly revenue of $7.8 billion, exceeding analyst expectations, and declared a quarterly dividend of $0.82 per share. Despite some insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $158.04, fueled by positive developments in its HIV franchise and an expanding oncology portfolio.
Trust Co. of Vermont Purchases Shares of 12,339 Gilead Sciences, Inc. $GILD
Trust Co. of Vermont recently acquired a new stake of 12,339 shares in Gilead Sciences, Inc., valued at approximately $1.56 million. This move is part of broader institutional interest, with other major firms like Norges Bank and Boston Partners also significantly increasing their holdings in the biopharmaceutical company. Gilead Sciences reported stronger-than-expected Q2 earnings and revenue, and its stock has seen a 3.3% increase recently, trading at $143.44.
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS
Handelsbanken Fonder AB has acquired a new stake worth approximately $1.20 million in Arcus Biosciences, Inc. (NYSE:RCUS) during the second quarter. Institutional investors collectively own 92.89% of the company, and analysts maintain a "Moderate Buy" consensus rating with a $37.80 average price target. The company reported a quarterly loss of $0.72 per share, beating estimates, and revenues of $41 million, which exceeded expectations despite a year-over-year decrease.
840,400 Shares in Gilead Sciences, Inc. $GILD Purchased by Danske Bank A S
Danske Bank A S recently acquired 840,400 shares of Gilead Sciences (NASDAQ:GILD), valued at approximately $106.2 million, as detailed in its latest SEC filing. This purchase contributes to institutional investors collectively owning 83.67% of the biopharmaceutical company. Gilead reported strong quarterly revenues of $7.8 billion, exceeding analyst expectations, and declared a quarterly dividend of $0.82 per share, while analysts maintain a "Moderate Buy" rating with an average price target of $158.04 despite some recent downgrades.
Gilead Sciences Insider Sold Shares Worth $3,853,908, According to a Recent SEC Filing
An insider at Gilead Sciences recently sold shares valued at $3,853,908, as reported in a recent SEC filing. The article highlights this transaction and provides an overview of Gilead Sciences' company profile, including its revenue breakdown by therapeutic products and geographical distribution. It also lists recent news and analyst ratings concerning the company.
Gilead Sciences CFO Andrew Dickinson sells $415k in shares
Gilead Sciences CFO Andrew Dickinson sold 3,000 shares of company stock for $138.36 per share, totaling $415,080, on August 17, 2026. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. Despite the sale, Dickinson still beneficially owns 165,646 shares, and the stock has seen an 18% year-to-date increase, although InvestingPro analysis suggests it may be overvalued.
Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock
Gilead Sciences CFO Andrew Dickinson sold 3,000 shares of the company's stock for $415,080 under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by 1.78%. This sale comes as Gilead's stock rose 3.3% to $143.44, following better-than-expected quarterly results and a declared dividend of $0.82 per share. The company maintains a "Moderate Buy" consensus from analysts, with institutional investors holding a significant portion of its shares.
Gilead Sciences CFO Andrew Dickinson sells $415k in shares
Gilead Sciences CFO Andrew Dickinson sold 3,000 shares of the company's common stock for $415,080 on August 17, 2026, as part of a Rule 10b5-1 trading plan. Despite the sale, Dickinson still beneficially owns 165,646 shares. This transaction follows Gilead's strong second-quarter 2026 results, which exceeded Wall Street expectations, and recent strategic collaborations, including an option exercise with MacroGenics.
Gilead Sciences chief comm & corp aff officer sells $3.85m stock
Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), sold 28,000 shares of company stock for approximately $3.85 million on August 17, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred alongside the exercise of non-qualified stock options to acquire 25,000 shares. Following these transactions, Mercier directly holds 118,234 shares and 69,960 non-qualified stock options.
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Stock
Gilead Sciences insider Johanna Mercier sold 28,000 shares of GILD stock for $3.85 million at an average price of $137.64, reducing her holdings by 19.15%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Gilead's stock traded up 3.3% to $143.44, and the company reported strong quarterly earnings and revenue that exceeded analyst estimates, maintaining a "Moderate Buy" consensus rating among analysts.
Gilead (NASDAQ: GILD) CFO sells shares under 10b5-1 plan
Gilead Sciences, Inc. (NASDAQ: GILD) Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on August 17, 2026, at a price of $138.36 per share. This transaction was carried out under a pre-adopted Rule 10b5-1 trading plan. After the sale, Mr. Dickinson directly holds 165,646 shares of the company's common stock.
Gilead Sciences Inc (GILD) Stock Up 3.2% but GF Value Says Overvalued
Gilead Sciences Inc (GILD) shares increased by 3.2% to $143.44, but GuruFocus's GF Value indicates the stock is 34.9% overvalued, with an estimated intrinsic value of $106.32. The company's GF Score is 74/100, highlighting strong profitability but weak momentum and insider selling of $77.5 million over the past year, signaling caution for investors. Its current forward P/E of 45.5x is also significantly higher than its historical median, reinforcing the overvaluation assessment.
Gilead Sciences Inc Stock (GILD) Moved Up by 3.14% on Aug 18: Drivers Behind the Movement
Gilead Sciences Inc (GILD) stock rose 3.14% on August 18, driven by a federal court injunction protecting its HIV medications, robust base-business revenue growth, and strategic oncology investments. Positive market sentiment was also fueled by bullish institutional options activity and strong fundamental performance, despite some company-specific risks like acquisition-driven net losses and increased debt leverage. Technical indicators showed a buy signal, though media coverage was low.
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead Sciences is expanding its market-leading HIV franchise with strong performance from Biktarvy and Descovy, and significant uptake of its new twice-yearly injectable, Yeztugo. The company has raised its full-year HIV sales growth guidance, driven by its PrEP business and a robust pipeline, including potential new drug applications and collaborations with Merck. Despite competition from GSK and Merck, Gilead's strategic expansions and potential blockbuster drugs are expected to bolster its long-term growth in the HIV market, though near-term profitability is affected by integration costs.
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Gilead Sciences Inc. (GILD) stock saw a daily gain of 3.25% on Tuesday, closing at $143.44. Despite this increase, the stock underperformed compared to broader market indices, with the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) also experiencing declines. This marked the stock's sixth consecutive day of gains.
